MDLinx

Home
MDLinx

Where science meets society: bite-sized medical news and insights for today’s dynamic physician. https://linktr.ee/mdlinxmarketing

20/08/2026

Bilateral salpingectomy fails in roughly 1 in 5 cesareans. Adhesions, usually, and it gets tougher after three or more prior C-sections.

When it does work, the cost is small: about 6 minutes at cesarean and 16 at hysterectomy, across a 320,443-patient analysis, with no increase in complications. "A straightforward salpingectomy in normal anatomy might only add a few minutes," Dr. Greg Marchand told MDLinx; the variable is what you find once you're actually in there.

At how many prior cesareans do you stop attempting bilateral? https://tinyurl.com/24atmufx

07/08/2026

The neurotoxicity from CAR T and bispecific T-cell engagers doesn’t always align with the grading scales that oncology teams rely on. New AANAI 2026 data quantify the risk and flag a major pitfall in paraneoplastic antibody testing: https://tinyurl.com/2m8tmfty

05/08/2026

Retatrutide isn't FDA-approved. Doesn't mean your patients haven't already heard about it.

The early numbers are strong: 30% average weight loss at 104 weeks in obesity trials, 21–23% at the highest dose in type 2 diabetes and cardiovascular trials.

"I can't say there's an ideal patient for Reta," one endocrinologist told MDLinx. Tolerability and long-term adherence are still what determine fit, not the trial readout alone.

MDLinx has the full breakdown, including where obesity medicine specialists are actually landing on this: https://tinyurl.com/3s577rfm

27/07/2026

21% → 6%. That's the post-discharge no-show rate for patients who completed a standardized transitional care call, compared to those who couldn't be reached. 52% of patients completed the call, and completing it cut no-shows by more than three times.

No new staff. No new tech. Just a call script that got made standard. Fewer missed follow-ups means you catch post-discharge complications earlier, in the window where a readmission either happens or doesn't.

One of the simplest ideas ACU 2026 put real data behind this year.

🔗https://tinyurl.com/bdz2fjd9

17/07/2026

Pharma brands work hard to reach physicians. What's even harder? Earning their attention.

MDLinx just became a 2026 MM+M Award finalist in Digital HCP Solutions for Second Opinion 🎉

Doctors are fielding more patient questions than ever about wellness trends, longevity hacks, and health content they've seen online. Second Opinion meets that moment head-on, turning misaligned expectations into real clinical conversations.

It's not a banner. It's not a content hub. It's a tool physicians actually use, every day.

Proud of the team behind it, and the physician community whose voice shaped it.

See it for yourself 👉 https://tinyurl.com/4p6syd49

13/07/2026

Plasma p-tau217 can detect Alzheimer's pathology more than 15 years before death. And its accuracy stays stable across that entire window (AUC 0.90–0.907), per autopsy-confirmed AAIC 2026 data.

The catch: liver dysfunction inflates results. In one liver-transplant cohort, 32% of patients converted from positive to negative post-transplant on standard p-tau217 — but brain-derived p-tau217 didn't budge.

Translation: the marker is ready for practice. Knowing which version you're ordering is no longer optional.

🔗 Full AAIC 2026 breakdown on MDLinx — https://tinyurl.com/v8x2v27z

12/07/2026

82% of primary care visits with a documented cognitive concern end without an MCI or Alzheimer's diagnosis being recorded, according to AAIC 2026 data spanning 35,649 visits.

Meanwhile, the detection tools are outpacing the workflow: plasma p-tau217 (AUC 0.901), EHR-based ML models predicting diagnosis a year out (AUROC 0.853), and smartphone cognitive composites are all validated and available.

The gap isn't the science; it's translating a positive signal into a documented, staged diagnosis.

More on MDLinx: https://tinyurl.com/v8x2v27z

08/07/2026

About one-third of patients with HER2+ metastatic breast cancer develop brain metastases. Tucatinib transformed outcomes once CNS disease is established, but whether it should be used proactively to prevent it remains unproven.

Calea Driscoll Bastnagel, PharmD, BCOP, works through the proactive-vs-reactive question on MDLinx: what HER2CLIMB-05 does and doesn't show, why the CNS-prevention data gap matters, and how to counsel patients while the evidence is still unsettled.

A real clinical dilemma, reasoned from the trial data rather than mechanism or theory.

Read the full analysis: https://tinyurl.com/43dp9ejc

01/07/2026

Could a short course of immunotherapy replace surgery for some re**al cancer patients?

At ESMO GI 2026, the RESET-R trial put that question to the test, and all 15 patients with dMMR re**al cancer achieved a complete clinical response after just 1 or 2 cycles, with no recurrences at 12 months. No surgery, no radiation.

It's an early, single-arm signal, but a striking one for organ preservation. We’re tracking the GI findings most likely to change your practice. Read the full breakdown and tell us which one you'd act on first. https://tinyurl.com/3bs8kw72

29/06/2026

A new class of lymphoma drugs, BTK degraders, has been working even in patients who stopped responding to older targeted therapies.

At AACR Lymphoma 2026, researchers found a single mutation that can resist all of them, but also discovered it's fragile, fading away once the drug is removed. That weakness points toward smarter drug combinations.

See the mechanism → https://tinyurl.com/2a4nyb6e

Address

Website

http://www.mdlinx.com/

Alerts

Be the first to know and let us send you an email when MDLinx posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to MDLinx:

Want your practice to be the top-listed Clinic?

Country:

City: